Noel Hutley

China’s largest state-run conglomerate CITIC has asked the High Court to hear its appeal in mega litigation with Clive Palmer’s Mineralogy over the $12 billion Sino Iron project in Western Australia. 

Law firm Allen & Overy advised that there were “very serious problems” with awarding Keybridge’s former CEO Nicholas Bolton a $4.75 million bonus, a judge has heard.

A class action on behalf of public housing residents in the Northern Territory has lost its appeal of a judge's decision to split an upcoming trial. 

A judge has allowed a 50 per cent fee uplift for counsel in an epic fight over lucrative tenements in the Pilbara region, but says the hourly fees of solicitors from the likes of Allens, Clayton Utz and Corrs were already well above market rate.

Former Keybridge CEO Nicholas Bolton has faced questions about a $4.75 million bonus he was paid on a $17.8 million deal with fund manager Magellan, on the second day of trial in proceedings by WAM over two transactions its alleges were oppressive to shareholders.

The lead shareholder in class actions against CBA has urged the High Court to take a "common sense" approach to loss causation in securities cases, as endorsed by the Full Federal Court in last month's ruling for Worley's investors.

A class action by public housing tenants in the Northern Territory claims a judge's decision to split the trial was based on a misunderstanding of fact and will lead to a "multiplicity of appeals".

Social media app Giggle for Girls has asked the High Court to reverse a finding that it committed direct discrimination on the basis of gender identity by excluding a transgender woman from its platform.

Clive Palmer’s Mineralogy has prevailed in an appeal as part of so-called mega litigation brought by CITIC over the $12 billion Sino Iron project in WA, with the court taking aim at both sides for the "intolerable" cost to the community of their endless dispute.

Kicking off its appeal of a finding that it couldn't walk away from a $672 million merger agreement with Mayne Pharma, US drug company Cosette has told a court that Mayne was not upfront about its financial position prior to the deal.